Amyloid and tau‐PET in early‐onset AD: baseline data from the longitudinal early‐onset Alzheimer's disease study (LEADS)
H Cho, NS Mundada, LG Apostolova… - Alzheimer's & …, 2023 - Wiley Online Library
Alzheimer's & Dementia, 2023•Wiley Online Library
INTRODUCTION We aimed to describe baseline amyloid‐beta (Aβ) and tau‐positron
emission tomograrphy (PET) from Longitudinal Early‐onset Alzheimer's Disease Study
(LEADS), a prospective multi‐site observational study of sporadic early‐onset Alzheimer's
disease (EOAD). METHODS We analyzed baseline [18F] Florbetaben (Aβ) and [18F]
Flortaucipir (tau)‐PET from cognitively impaired participants with a clinical diagnosis of mild
cognitive impairment (MCI) or AD dementia aged< 65 years. Florbetaben scans were used …
emission tomograrphy (PET) from Longitudinal Early‐onset Alzheimer's Disease Study
(LEADS), a prospective multi‐site observational study of sporadic early‐onset Alzheimer's
disease (EOAD). METHODS We analyzed baseline [18F] Florbetaben (Aβ) and [18F]
Flortaucipir (tau)‐PET from cognitively impaired participants with a clinical diagnosis of mild
cognitive impairment (MCI) or AD dementia aged< 65 years. Florbetaben scans were used …
INTRODUCTION
We aimed to describe baseline amyloid‐beta (Aβ) and tau‐positron emission tomograrphy (PET) from Longitudinal Early‐onset Alzheimer's Disease Study (LEADS), a prospective multi‐site observational study of sporadic early‐onset Alzheimer's disease (EOAD).
METHODS
We analyzed baseline [18F]Florbetaben (Aβ) and [18F]Flortaucipir (tau)‐PET from cognitively impaired participants with a clinical diagnosis of mild cognitive impairment (MCI) or AD dementia aged < 65 years. Florbetaben scans were used to distinguish cognitively impaired participants with EOAD (Aβ+) from EOnonAD (Aβ−) based on the combination of visual read by expert reader and image quantification.
RESULTS
243/321 (75.7%) of participants were assigned to the EOAD group based on amyloid‐PET; 231 (95.1%) of them were tau‐PET positive (A+T+). Tau‐PET signal was elevated across cortical regions with a parietal‐predominant pattern, and higher burden was observed in younger and female EOAD participants.
DISCUSSION
LEADS data emphasizes the importance of biomarkers to enhance diagnostic accuracy in EOAD. The advanced tau‐PET binding at baseline might have implications for therapeutic strategies in patients with EOAD.
HIGHLIGHTS
- 72% of patients with clinical EOAD were positive on both amyloid‐ and tau‐PET.
- Amyloid‐positive patients with EOAD had high tau‐PET signal across cortical regions.
- In EOAD, tau‐PET mediated the relationship between amyloid‐PET and MMSE.
- Among EOAD patients, younger onset and female sex were associated with higher tau‐PET.
Wiley Online Library以上显示的是最相近的搜索结果。 查看全部搜索结果